Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses RMD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RMD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Farrell | $1,214,150 | $0 | $8,775,059 | $2,925,007 | $1,646,743 | $0 | $113,584 | $14,674,543 |
| Chairman of the Board and Chief Executive Officer | ||||||||
| Justin Leong | 677,032 | 0 | 2,600,037 | 0 | 552,478 | 0 | 81,894 | 3,911,441 |
| Chief Product Officer | ||||||||
| Bobby Ghoshal | 651,660 | 0 | 2,400,078 | 0 | 550,001 | 0 | 50,716 | 3,652,455 |
| Chief Commercial Officer, Residential Care Software | ||||||||
| Brett Sandercock | 498,967 | 0 | 2,600,037 | 0 | 407,171 | 0 | 65,835 | 3,572,010 |
| Chief Financial Officer | ||||||||
| Michael Rider | 508,745 | 0 | 1,400,005 | 0 | 311,363 | 0 | 69,009 | 2,289,122 |
| Global General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Farrell | $14,674,543 | — | — | — |
| Justin Leong | 3,911,441 | — | — | — |
| Bobby Ghoshal | 3,652,455 | — | — | — |
| Brett Sandercock | 3,572,010 | — | — | — |
| Michael Rider | 2,289,122 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | D | 8,009 | $283 | $2,265,332 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | A | 8,009 | 102 | 814,035 | Common | Form 4 ↗ |
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | D | 8,009 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | A | 2,000 | 102 | 203,280 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | D | 3,000 | 248 | 742,620 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | D | 8,011 | 250 | 2,000,773 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-11-07 | — | 983 | — | — | 1 insider, 1 accrual row | ||
| Michael J. Farrell | Director | 2025-11-07 | A | 7,028 | 102 | 714,326 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | D | 7,028 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | A | 983 | 102 | 99,912 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 2,231.55 | 250 | 558,109 | Common | Form 4 ↗ |
| Harjit Gill | Director | 2025-11-11 | D | 38.21 | 250 | 9,556 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 3,459.33 | 250 | 865,177 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-11 | D | 76.45 | 250 | 19,120 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 715.49 | 250 | 178,944 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 135.08 | 250 | 33,782 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-11 | D | 487 | 250 | 121,872 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-11 | D | 162.95 | 250 | 40,755 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 173.73 | 250 | 43,449 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-11 | D | 2,000 | 252 | 504,100 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 500.74 | 250 | 125,234 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 2,205.7 | 250 | 551,645 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | A | 11,442 | 102 | 1,162,965 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | D | 7,314 | 244 | 1,787,980 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | D | 11,442 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald Taylor | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-20 | A | 2,710 | 0 | 0 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-20 | A | 13,551 | 0 | 0 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-20 | A | 536 | 0 | 0 | Common | Form 4 ↗ |
| John Hernandez | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Karen Drexler | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Christopher DelOrefice | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Harjit Gill | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Justin Leong | Chief Product Officer | 2025-11-20 | A | 1,848 | 0 | 0 | Common | Form 4 ↗ |
| Nicole Mowad-Nassar | Director | 2025-11-20 | A | 536 | 0 | 0 | Common | Form 4 ↗ |
| Desney Tan | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Carol Burt | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-20 | D | 7,297 | 0 | 0 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-24 | A | 1,331 | 251 | 333,442 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-24 | A | 33,288 | 251 | 8,339,310 | Derivative, Class A Common | Form 4 ↗ |
| Nicole Mowad-Nassar | Director | 2025-11-24 | A | 1,331 | 251 | 333,442 | Derivative, Class A Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-25 | D | 2,055 | 255 | 524,025 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-12-01 | D | 50 | 244 | 12,208 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-12-01 | D | 1,000 | 244 | 244,160 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-12-03 | D | 2,000 | 251 | 502,940 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | D | 4,991 | 251 | 1,254,796 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-01-02 | D | 50 | 242 | 12,088 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-01-02 | D | 1,000 | 242 | 241,750 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-01-07 | D | 2,000 | 249 | 497,660 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | D | 4,991 | 248 | 1,240,065 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-02-02 | D | 1,000 | 257 | 257,030 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-02-04 | D | 50 | 260 | 13,000 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-02-04 | D | 2,000 | 251 | 502,620 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | D | 4,991 | 274 | 1,366,436 | Common, open-market sale | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-03-02 | D | 1,000 | 254 | 254,300 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-03-04 | D | 2,000 | 260 | 520,440 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | D | 4,991 | 251 | 1,252,902 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-04-01 | D | 1,000 | 224 | 224,310 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-04-01 | D | 2,000 | 225 | 450,000 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | D | 4,991 | 226 | 1,125,486 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | D | 4,991 | 208 | 1,037,233 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-06-01 | D | 268.74 | 191 | 51,214 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | D | 4,991 | 194 | 968,064 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | D | 4,991 | 219 | 1,090,771 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | D | 8,009 | $283 | $2,265,332 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | A | 8,009 | 102 | 814,035 | Common | Form 4 ↗ |
| Michael J. Farrell | Chief Executive Officer | 2025-10-07 | D | 8,009 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | A | 2,000 | 102 | 203,280 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | D | 3,000 | 248 | 742,620 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-03 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | D | 8,011 | 250 | 2,000,773 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | D | 983 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | A | 7,028 | 102 | 714,326 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | D | 7,028 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-07 | A | 983 | 102 | 99,912 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 2,231.55 | 250 | 558,109 | Common | Form 4 ↗ |
| Harjit Gill | Director | 2025-11-11 | D | 38.21 | 250 | 9,556 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 3,459.33 | 250 | 865,177 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-11 | D | 76.45 | 250 | 19,120 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 715.49 | 250 | 178,944 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 135.08 | 250 | 33,782 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-11 | D | 487 | 250 | 121,872 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-11 | D | 162.95 | 250 | 40,755 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 173.73 | 250 | 43,449 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-11 | D | 2,000 | 252 | 504,100 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-11-11 | D | 500.74 | 250 | 125,234 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-11 | D | 2,205.7 | 250 | 551,645 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | A | 11,442 | 102 | 1,162,965 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | D | 7,314 | 244 | 1,787,980 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-14 | D | 11,442 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald Taylor | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-11-20 | A | 2,710 | 0 | 0 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-20 | A | 13,551 | 0 | 0 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-20 | A | 536 | 0 | 0 | Common | Form 4 ↗ |
| John Hernandez | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Karen Drexler | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Christopher DelOrefice | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Harjit Gill | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Justin Leong | Chief Product Officer | 2025-11-20 | A | 1,848 | 0 | 0 | Common | Form 4 ↗ |
| Nicole Mowad-Nassar | Director | 2025-11-20 | A | 536 | 0 | 0 | Common | Form 4 ↗ |
| Desney Tan | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Carol Burt | Director | 2025-11-20 | A | 1,073 | 0 | 0 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-20 | D | 7,297 | 0 | 0 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-11-24 | A | 1,331 | 251 | 333,442 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-11-24 | A | 33,288 | 251 | 8,339,310 | Derivative, Class A Common | Form 4 ↗ |
| Nicole Mowad-Nassar | Director | 2025-11-24 | A | 1,331 | 251 | 333,442 | Derivative, Class A Common | Form 4 ↗ |
| Jan De Witte | Director | 2025-11-25 | D | 2,055 | 255 | 524,025 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2025-12-01 | D | 50 | 244 | 12,208 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2025-12-01 | D | 1,000 | 244 | 244,160 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2025-12-03 | D | 2,000 | 251 | 502,940 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | D | 4,991 | 251 | 1,254,796 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2025-12-08 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-01-02 | D | 50 | 242 | 12,088 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-01-02 | D | 1,000 | 242 | 241,750 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-01-07 | D | 2,000 | 249 | 497,660 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | D | 4,991 | 248 | 1,240,065 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-01-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-02-02 | D | 1,000 | 257 | 257,030 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-02-04 | D | 50 | 260 | 13,000 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-02-04 | D | 2,000 | 251 | 502,620 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-02-09 | D | 4,991 | 274 | 1,366,436 | Common, open-market sale | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-03-02 | D | 1,000 | 254 | 254,300 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-03-04 | D | 2,000 | 260 | 520,440 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | D | 4,991 | 251 | 1,252,902 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-03-09 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett Sandercock | Chief Financial Officer | 2026-04-01 | D | 1,000 | 224 | 224,310 | Common | Form 4 ↗ |
| Peter C. Farrell | Director | 2026-04-01 | D | 2,000 | 225 | 450,000 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | D | 4,991 | 226 | 1,125,486 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-04-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | D | 4,991 | 208 | 1,037,233 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-05-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael Rider | Global General Counsel | 2026-06-01 | D | 268.74 | 191 | 51,214 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-06-08 | D | 4,991 | 194 | 968,064 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | D | 4,991 | 219 | 1,090,771 | Common, open-market sale | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | D | 4,991 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Farrell | Director | 2026-07-07 | A | 4,991 | 146 | 730,383 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brett Sandercock | RSU | 2024-11-20 | 2,731 | 5,462 | — | 5,462 | $1,300,065 |
| Bobby Ghoshal | PSU | 2024-11-20 | 970 | 2,155 | — | 4,310 | 600,060 |
| Michael Rider | RSU | 2024-11-20 | 1,471 | 2,941 | — | 2,941 | 700,017 |
| Michael Rider | PSU | 2024-11-20 | 566 | 1,257 | — | 2,514 | 350,012 |
| Brett Sandercock | PSU | 2024-11-20 | 1,050 | 2,334 | — | 4,668 | 649,902 |
| Bobby Ghoshal | RSU | 2024-11-20 | 2,521 | 5,042 | — | 5,042 | 1,200,097 |
| Michael Farrell | PSU | 2024-11-20 | 5,483 | 10,965 | — | 21,930 | 2,924,914 |
| Justin Leong | PSU | 2024-11-20 | 1,050 | 2,334 | — | 4,668 | 649,902 |
| Justin Leong | RSU | 2024-11-20 | 2,731 | 5,462 | — | 5,462 | 1,300,065 |
| Justin Leong | PSU | 2024-11-20 | 1,219 | 2,437 | — | 4,874 | 650,070 |
| Brett Sandercock | PSU | 2024-11-20 | 1,219 | 2,437 | — | 4,874 | 650,070 |
| Michael Farrell | OPTION | 2024-11-25 | — | — | 33,036 | — | 2,925,007 |
| Bobby Ghoshal | PSU | 2024-11-20 | 1,125 | 2,249 | — | 4,498 | 599,921 |
| Michael Rider | PSU | 2024-11-20 | 656 | 1,312 | — | 2,624 | 349,976 |
| Michael Farrell | PSU | 2024-11-20 | 4,727 | 10,505 | — | 21,010 | 2,925,117 |
| Michael Farrell | RSU | 2024-11-20 | 6,145 | 12,289 | — | 12,289 | 2,925,028 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brett Sandercock | $1,300,065 | $1,299,972 | $0 | 50.0% |
| Bobby Ghoshal | 1,200,097 | 1,199,981 | 0 | 50.0% |
| Michael Rider | 700,017 | 699,988 | 0 | 50.0% |
| Michael Farrell | 2,925,028 | 5,850,031 | 2,925,007 | 50.0% |
| Justin Leong | 1,300,065 | 1,299,972 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Farrell | Option | 59,894 | 146.34 | — |
| Farrell | Option | 36,979 | 148.9 | — |
| Bobby Ghoshal | PSU | 5,042 | — | 1,300,836 |
| Michael Rider | PSU | 3,330 | — | 859,140 |
| Brett Sandercock | RSU | 2,239 | — | 577,662 |
| Bobby Ghoshal | RSU | 1,125 | — | 290,250 |
| Justin Leong | RSU | 1,102 | — | 284,316 |
| Justin Leong | Option | 3,325 | 224.58 | — |
| Michael Rider | PSU | 2,941 | — | 758,778 |
| Farrell | PSU | 12,289 | — | 3,170,562 |
| Farrell | RSU | 33,826 | — | 8,727,108 |
| Brett Sandercock | RSU | 6,946 | — | 1,792,068 |
| Bobby Ghoshal | RSU | 2,239 | — | 577,662 |
| Farrell | RSU | 11,192 | — | 2,887,536 |
| Michael Rider | RSU | 1,886 | — | 486,588 |
| Farrell | RSU | 5,483 | — | 1,414,614 |
| Justin Leong | PSU | 5,462 | — | 1,409,196 |
| Brett Sandercock | RSU | 1,836 | — | 473,688 |
| Brett Sandercock | RSU | 3,501 | — | 903,258 |
| Justin Leong | RSU | 1,526 | — | 393,708 |
| Michael Rider | RSU | 3,926 | — | 1,012,908 |
| Brett Sandercock | RSU | 1,219 | — | 314,502 |
| Justin Leong | RSU | 3,501 | — | 903,258 |
| Bobby Ghoshal | RSU | 6,106 | — | 1,575,348 |
| Justin Leong | RSU | 878 | — | 226,524 |
| Bobby Ghoshal | RSU | 841 | — | 216,978 |
| Bobby Ghoshal | RSU | 3,233 | — | 834,114 |
| Bobby Ghoshal | RSU | 6,946 | — | 1,792,068 |
| Justin Leong | RSU | 1,219 | — | 314,502 |
| Bobby Ghoshal | PSU | 5,891 | — | 1,519,878 |
| Farrell | RSU | 8,261 | — | 2,131,338 |
| Justin Leong | RSU | 7,248 | — | 1,869,984 |
| Brett Sandercock | RSU | 6,935 | — | 1,789,230 |
| Farrell | Option | 33,036 | 249.56 | — |
| Michael Rider | RSU | 656 | — | 169,248 |
| Farrell | PSU | 28,686 | — | 7,400,988 |
| Farrell | RSU | 15,758 | — | 4,065,564 |
| Justin Leong | PSU | 6,146 | — | 1,585,668 |
| Brett Sandercock | PSU | 5,891 | — | 1,519,878 |
| Michael Rider | RSU | 4,678 | — | 1,206,924 |
| Brett Sandercock | PSU | 5,462 | — | 1,409,196 |
| Michael Rider | RSU | 476 | — | 122,808 |
| Bobby Ghoshal | RSU | 1,607 | — | 414,606 |
| Justin Leong | RSU | 5,506 | — | 1,420,548 |
| Brett Sandercock | RSU | 841 | — | 216,978 |
| Farrell | RSU | 16,992 | — | 4,383,936 |
| Farrell | RSU | 4,098 | — | 1,057,284 |
| Farrell | Option | 12,190 | 224.58 | — |
| Brett Sandercock | Option | 10,883 | 101.64 | — |
| Farrell | Option | 40,047 | 101.64 | — |
| Bobby Ghoshal | Option | 2,438 | 224.58 | — |
Our goal is to attract, motivate, and retain top global talent reflecting our values, enabling us to achieve our short- and long-term strategic goals. Pay-for-performance aligned with stockholder interests and overwhelmingly at-risk compensation are the cornerstones of our compensation program.
| CEO STI target (% of salary) | 135% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-11-19 | 98,435,762 | 11,004,916 | 236,395 | 89.94% | Passed |
| 2024 | 2024-11-20 | 92,885,004 | 17,284,647 | 87,620 | 84.31% | Passed |
| 2023 | 2023-11-16 | 84,318,661 | 19,649,791 | 77,972 | 81.1% | Passed |
| 2022 | 2022-11-16 | 103,364,254 | 11,566,190 | 254,814 | 89.94% | Passed |
| 2021 | 2021-11-18 | 99,221,728 | 12,231,321 | 220,184 | 89.03% | Passed |
| 2020 | 2020-11-19 | 101,981,838 | 9,669,839 | 137,628 | 91.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-11-19 | 89.94%a |
| 2024 | 2024-11-20 | 84.31%b |
| 2023 | 2023-11-16 | 81.1%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes do not count as votes cast and thus will not affect the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes do not count as votes cast and thus will not affect the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes do not count as votes cast and 5 Table of Contents thus will not affect the outcome of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 187 : 1 |
|---|---|
| CEO total compensation | $14,674,543 |
| Median employee compensation | $78,354 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter FarrellEmployee director | $70,000 | $130,075 | $129,977 | — | $343,214 | $673,266 |
| Christopher DelOreficeIndependent · Audit (Chair) | 53,000 | 324,745 | 0 | 0 | 0 | 377,745 |
| Ronald TaylorIndependent · Lead Independent Director · Audit · Compliance, Privacy and Quality · Nominating and Governance | 110,000 | 259,909 | 0 | 0 | 0 | 369,909 |
| Carol BurtIndependent · Audit · Compliance, Privacy and Quality · Nominating and Governance (Chair) | 106,810 | 259,909 | 0 | 0 | 0 | 366,719 |
| Karen DrexlerIndependent · Compensation and Leadership Development (Chair) · Nominating and Governance | 90,000 | 259,909 | 0 | 0 | 0 | 349,909 |
| Richard SulpizioIndependent · Audit · Compensation and Leadership Development · Nominating and Governance · Not standing for re-election | 85,000 | 259,909 | 0 | 0 | 0 | 344,909 |
| Harjit GillIndependent · Audit · Compensation and Leadership Development · Compliance, Privacy and Quality (Chair) | 73,190 | 259,909 | 0 | 0 | 0 | 333,099 |
| Jan De WitteIndependent · Audit · Compliance, Privacy and Quality | 70,000 | 259,909 | 0 | 0 | 0 | 329,909 |
| John HernandezIndependent · Compliance, Privacy and Quality | 70,000 | 259,909 | 0 | 0 | 0 | 329,909 |
| Desney TanIndependent · Compensation and Leadership Development · Nominating and Governance | 70,000 | 259,909 | 0 | 0 | 0 | 329,909 |
| Nicole Mowad-NassarIndependent · Compensation and Leadership Development · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Michael FarrellEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $798,000 |
| Equity awards (grant-date value) | $2,534,092 |
| All other compensation | $343,214 |
| Total cost of the board | $3,675,306 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies ResMed Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including ResMed Inc.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Baxter International, Inc. | 2025 | Andrew Hider | $499,315 | $23,133,518 | $3,185,053 | $820,125 | $29,805,182 |
| 2 | Intuitive Surgical, Inc. | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 3 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 4 | Edwards Lifesciences Corp. | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 5 | The Cooper Companies Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 6 | Hologic Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 7 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 8 | ResMed Inc | 2025 | Michael Farrell | 1,214,150 | 8,775,059 | 2,925,007 | 1,646,743 | 14,674,543 |
| 9 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 10 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 11 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 12 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 13 | STERIS plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 14 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 15 | Dentsply Sirona Inc. | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 16 | Amcor | 2025 | Peter Konieczny | 1,822,278 | 3,879,938 | 996,984 | 1,403,397 | 8,458,329 |
| 17 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 18 | Dexcom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 19 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 20 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 21 | James Hardie Industries PLC | 2026 | Aaron Erter | 1,120,335 | 4,658,716 | 0 | 703,872 | 6,545,953 |
| — | REA Group | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ResMed Inc | 102% | PSU 50 · RSU 25 · Options 25 | Yes — Absolute TSR | FW Cook, Inc. |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Amcor | 71% | PSU 50 · Options 50 | Yes — Relative TSR | FW Cook and Willis Towers Watson |
| Baxter International, Inc. | not disclosed | PSU 50 · Stock Options 25 · RSU 25 | not disclosed | Aon |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Dentsply Sirona Inc. | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| Dexcom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corp. | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Hologic Inc. | 109% | PSU 50 · RSU 25 · Options 25 | No | not disclosed |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| James Hardie Industries PLC | 45% | PSU 66 · Cash LTI 34 | Yes — Relative TSR | FW Cook (United States) and Guerdon Associates (Australia) |
| Mettler-Toledo International Inc. | 80% | PSU 33 · RSU 33 · Options 33 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners (PM&P) |
| REA Group | not disclosed | not disclosed | not disclosed | not disclosed |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| STERIS plc | 125.1% | RSU 50 · Options 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Farrell | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Summary Compensation Table” · page 75. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678 |
| 2 | Section 01, Justin Leong | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Summary Compensation Table” · page 75. As printed: 3,911,441. Filing ↗machine: span 1355054–1355063 |
| 3 | Section 01, Bobby Ghoshal | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Summary Compensation Table” · page 75. As printed: 3,652,455. Filing ↗machine: span 1341867–1341876 |
| 4 | Section 01, Brett Sandercock | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Summary Compensation Table” · page 75. As printed: 3,572,010. Filing ↗machine: span 1372108–1372117 |
| 5 | Section 01, Michael Rider | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Summary Compensation Table” · page 75. As printed: 2,289,122. Filing ↗machine: span 1363932–1363941 |
| 6 | Section 03, Brett Sandercock RSU | DEF 14A | — | 0000943819-25-000079 | Section “TSR M” · grants of plan-based awards table. Filing ↗machine: t198 · r29 · c16 · span 1594993–1594998 |
| 7 | Section 03, Bobby Ghoshal PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t194 · r8 · c20 · span 1446914–1446921 |
| 8 | Section 03, Michael Rider RSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t198 · r24 · c13 · span 1582502–1582507 |
| 9 | Section 03, Michael Rider PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t194 · r16 · c20 · span 1470694–1470701 |
| 10 | Section 03, Brett Sandercock PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t194 · r20 · c20 · span 1482616–1482623 |
| 11 | Section 03, Bobby Ghoshal RSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t198 · r10 · c17 · span 1550589–1550594 |
| 12 | Section 03, Michael Farrell PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 13 | Section 03, Justin Leong PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t194 · r12 · c20 · span 1458806–1458813 |
| 14 | Section 03, Justin Leong RSU | DEF 14A | — | 0000943819-25-000079 | Section “TSR M” · grants of plan-based awards table. Filing ↗machine: t198 · r17 · c17 · span 1567187–1567192 |
| 15 | Section 03, Justin Leong PSU | DEF 14A | — | 0000943819-25-000079 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 16 | Section 03, Brett Sandercock PSU | DEF 14A | — | 0000943819-25-000079 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 17 | Section 03, Michael Farrell OPTION | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t190 · r2 · c13 · span 1326732–1326741 |
| 18 | Section 03, Bobby Ghoshal PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 19 | Section 03, Michael Rider PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 20 | Section 03, Michael Farrell PSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t194 · r3 · c20 · span 1432389–1432398 |
| 21 | Section 03, Michael Farrell RSU | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t198 · r3 · c17 · span 1529443–1529449 |
| 22 | Section 07, pay ratio | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “CEO Pay Ratio”. As printed: 187 : 1. Filing ↗machine: span 1210243–1210246 |
| 23 | Section 08, Peter Farrell | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 673,266. Filing ↗machine: t121 · r6 · c19 · span 784177–784184 |
| 24 | Section 08, Christopher DelOrefice | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 377,745. Filing ↗machine: t121 · r4 · c15 · span 777285–777292 |
| 25 | Section 08, Ronald Taylor | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 369,909. Filing ↗machine: t121 · r11 · c15 · span 799154–799161 |
| 26 | Section 08, Carol Burt | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 366,719. Filing ↗machine: t121 · r2 · c15 · span 771493–771500 |
| 27 | Section 08, Karen Drexler | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 349,909. Filing ↗machine: t121 · r5 · c15 · span 780178–780185 |
| 28 | Section 08, Richard Sulpizio | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 344,909. Filing ↗machine: t121 · r9 · c15 · span 792858–792865 |
| 29 | Section 08, Harjit Gill | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 333,099. Filing ↗machine: t121 · r7 · c15 · span 787068–787075 |
| 30 | Section 08, Jan De Witte | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 329,909. Filing ↗machine: t121 · r3 · c15 · span 774383–774390 |
| 31 | Section 08, John Hernandez | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 329,909. Filing ↗machine: t121 · r8 · c15 · span 789962–789969 |
| 32 | Section 08, Desney Tan | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 329,909. Filing ↗machine: t121 · r10 · c15 · span 795748–795755 |
| 33 | Section 08, Nicole Mowad-Nassar | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 08, Michael Farrell | DEF 14A | 2025-10-02 | 0000943819-25-000079 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 02, Michael J. Farrell 2025-10-07 | Form 4 | 2025-10-09 | 0000943819-25-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Michael J. Farrell 2025-10-07 | Form 4 | 2025-10-09 | 0000943819-25-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Michael J. Farrell 2025-10-07 | Form 4 | 2025-10-09 | 0000943819-25-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Brett Sandercock 2025-11-03 | Form 4 | 2025-11-04 | 0000943819-25-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Brett Sandercock 2025-11-03 | Form 4 | 2025-11-04 | 0000943819-25-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Brett Sandercock 2025-11-03 | Form 4 | 2025-11-04 | 0000943819-25-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Michael J. Farrell 2025-11-07 | Form 4 | 2025-11-10 | 0000943819-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michael J. Farrell 2025-11-07 | Form 4 | 2025-11-10 | 0000943819-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Michael J. Farrell 2025-11-07 | Form 4 | 2025-11-10 | 0000943819-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michael J. Farrell 2025-11-07 | Form 4 | 2025-11-10 | 0000943819-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Michael J. Farrell 2025-11-07 | Form 4 | 2025-11-10 | 0000943819-25-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Michael J. Farrell 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Harjit Gill 2025-11-11 | Form 4 | 2025-11-14 | 0000943819-25-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Michael J. Farrell 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Jan De Witte 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Michael Rider 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Michael Rider 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Jan De Witte 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Peter C. Farrell 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Rider 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Peter C. Farrell 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Michael Rider 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael J. Farrell 2025-11-11 | Form 4 | 2025-11-13 | 0000943819-25-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Peter C. Farrell 2025-11-14 | Form 4 | 2025-11-18 | 0000943819-25-000122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Peter C. Farrell 2025-11-14 | Form 4 | 2025-11-18 | 0000943819-25-000122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Peter C. Farrell 2025-11-14 | Form 4 | 2025-11-18 | 0000943819-25-000122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Ronald Taylor 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Brett Sandercock 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Michael J. Farrell 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Peter C. Farrell 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, John Hernandez 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Karen Drexler 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Christopher DelOrefice 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Harjit Gill 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Jan De Witte 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Justin Leong 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Nicole Mowad-Nassar 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Desney Tan 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Carol Burt 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Michael J. Farrell 2025-11-20 | Form 4 | 2025-11-24 | 0000943819-25-000170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Peter C. Farrell 2025-11-24 | Form 4 | 2025-11-26 | 0000943819-25-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Michael J. Farrell 2025-11-24 | Form 4 | 2025-11-26 | 0000943819-25-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Nicole Mowad-Nassar 2025-11-24 | Form 4 | 2025-11-26 | 0000943819-25-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jan De Witte 2025-11-25 | Form 4 | 2025-11-26 | 0000943819-25-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Michael Rider 2025-12-01 | Form 4 | 2025-12-02 | 0000943819-25-000185 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Brett Sandercock 2025-12-01 | Form 4 | 2025-12-02 | 0000943819-25-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Peter C. Farrell 2025-12-03 | Form 4 | 2025-12-04 | 0000943819-25-000186 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Michael J. Farrell 2025-12-08 | Form 4 | 2025-12-09 | 0000943819-25-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Michael J. Farrell 2025-12-08 | Form 4 | 2025-12-09 | 0000943819-25-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Michael J. Farrell 2025-12-08 | Form 4 | 2025-12-09 | 0000943819-25-000187 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Michael Rider 2026-01-02 | Form 4 | 2026-01-05 | 0000943819-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Brett Sandercock 2026-01-02 | Form 4 | 2026-01-05 | 0000943819-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Peter C. Farrell 2026-01-07 | Form 4 | 2026-01-09 | 0000943819-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Michael J. Farrell 2026-01-07 | Form 4 | 2026-01-08 | 0000943819-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Michael J. Farrell 2026-01-07 | Form 4 | 2026-01-08 | 0000943819-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Michael J. Farrell 2026-01-07 | Form 4 | 2026-01-08 | 0000943819-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Brett Sandercock 2026-02-02 | Form 4 | 2026-02-03 | 0000943819-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Michael Rider 2026-02-04 | Form 4 | 2026-02-06 | 0000943819-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Peter C. Farrell 2026-02-04 | Form 4 | 2026-02-06 | 0000943819-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Michael J. Farrell 2026-02-09 | Form 4 | 2026-02-10 | 0000943819-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Michael J. Farrell 2026-02-09 | Form 4 | 2026-02-10 | 0000943819-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Michael J. Farrell 2026-02-09 | Form 4 | 2026-02-10 | 0000943819-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Brett Sandercock 2026-03-02 | Form 4 | 2026-03-03 | 0000943819-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Peter C. Farrell 2026-03-04 | Form 4 | 2026-03-05 | 0000943819-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Michael J. Farrell 2026-03-09 | Form 4 | 2026-03-11 | 0000943819-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Michael J. Farrell 2026-03-09 | Form 4 | 2026-03-11 | 0000943819-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Michael J. Farrell 2026-03-09 | Form 4 | 2026-03-11 | 0000943819-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Brett Sandercock 2026-04-01 | Form 4 | 2026-04-03 | 0000943819-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Peter C. Farrell 2026-04-01 | Form 4 | 2026-04-02 | 0000943819-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Michael J. Farrell 2026-04-07 | Form 4 | 2026-04-09 | 0000943819-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Michael J. Farrell 2026-04-07 | Form 4 | 2026-04-09 | 0000943819-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Michael J. Farrell 2026-04-07 | Form 4 | 2026-04-09 | 0000943819-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Michael J. Farrell 2026-05-07 | Form 4 | 2026-05-11 | 0000943819-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Michael J. Farrell 2026-05-07 | Form 4 | 2026-05-11 | 0000943819-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Michael J. Farrell 2026-05-07 | Form 4 | 2026-05-11 | 0000943819-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Michael Rider 2026-06-01 | Form 4 | 2026-06-03 | 0000943819-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Michael J. Farrell 2026-06-08 | Form 4 | 2026-06-09 | 0000943819-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Michael J. Farrell 2026-06-08 | Form 4 | 2026-06-09 | 0000943819-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Michael J. Farrell 2026-06-08 | Form 4 | 2026-06-09 | 0000943819-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Michael J. Farrell 2026-07-07 | Form 4 | 2026-07-09 | 0000943819-26-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Michael J. Farrell 2026-07-07 | Form 4 | 2026-07-09 | 0000943819-26-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Michael J. Farrell 2026-07-07 | Form 4 | 2026-07-09 | 0000943819-26-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 06, 2025 vote | Form 8-K | 2025-11-20 | 0001193125-25-289878 | Item 5.07 · say-on-pay result. As reported: 89.94% (votes for as printed: 98,435,762). Filing ↗ |
| 118 | Section 06, 2024 vote | Form 8-K | 2024-11-21 | 0001193125-24-263501 | Item 5.07 · say-on-pay result. As reported: 84.31% (votes for as printed: 92,885,004). Filing ↗ |
| 119 | Section 06, 2023 vote | Form 8-K | 2023-11-20 | 0001193125-23-280656 | Item 5.07 · say-on-pay result. As reported: 81.1% (votes for as printed: 84,318,661). Filing ↗ |
| 120 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 121 | Section 09b board cost (computed) | Computed | — | computed | Cash 798,000 + equity 2,534,092 + all other 343,214 = 3,675,306, summed across the director compensation table rows.machine: formula: Σ = 3,675,306 |
| 122 | Baxter International, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International, Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 123 | Intuitive Surgical, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001035267-26-000023 | CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299 |
| 124 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 125 | Edwards Lifesciences Corp., Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corp.'s own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 126 | The Cooper Companies Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 127 | Hologic Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 128 | Charles River Laboratories International, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 129 | ResMed Inc (subject), Section 10b CEO total | DEF 14A | 2025-10-02 | 0000943819-25-000079 | CEO total compensation as printed in ResMed Inc's own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678 |
| 130 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 131 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 132 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295 |
| 133 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 134 | STERIS plc, Section 10b CEO total | DEF 14A | 2026-06-11 | 0001193125-26-267599 | CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600 |
| 135 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 136 | Dentsply Sirona Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0000818479-26-000125 | CEO total compensation as printed in Dentsply Sirona Inc.'s own proxy. As printed: 8,760,139. Filing ↗machine: r5 · c27 · span 1201378–1201387 |
| 137 | Amcor, Section 10b CEO total | DEF 14A | 2025-09-23 | 0001748790-25-000032 | CEO total compensation as printed in Amcor's own proxy. As printed: 8,458,329. Filing ↗machine: t85 · r3 · c7 · span 1845231–1845240 |
| 138 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 139 | Dexcom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in Dexcom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 140 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 141 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 142 | James Hardie Industries PLC, Section 10b CEO total | DEF 14A | 2026-07-01 | 0001628280-26-046522 | CEO total compensation as printed in James Hardie Industries PLC's own proxy. As printed: 6,545,953. Filing ↗machine: r2 · c9 · span 2897477–2897486 |
| 143 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 144 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 145 | Section 10a, Hologic Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 146 | Section 10a, Intuitive Surgical, Inc. reciprocity | DEF 14A | — | 0001035267-26-000023 | Intuitive Surgical, Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 147 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 148 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 149 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include ResMed Inc. Filing ↗ |
| 150 | Section 10a, The Cooper Companies Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 151 | Section 10a, Dexcom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | Dexcom, Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 152 | Section 10a, Edwards Lifesciences Corp. reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corp. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 153 | Section 10a, Charles River Laboratories International, Inc. reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories International, Inc.'s most recent proxy was read; its disclosed peer group does not include ResMed Inc. Filing ↗ |
| 154 | Section 10a, Dentsply Sirona Inc. reciprocity | DEF 14A | — | 0000818479-26-000125 | Dentsply Sirona Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 155 | Section 10a, Amcor reciprocity | DEF 14A | — | 0001748790-25-000032 | Amcor's most recent proxy was read; its disclosed peer group does not include ResMed Inc. Filing ↗ |
| 156 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 157 | Section 10a, Baxter International, Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International, Inc.'s most recent proxy was read; its disclosed peer group does not include ResMed Inc. Filing ↗ |
| 158 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 159 | Section 10a, STERIS plc reciprocity | DEF 14A | — | 0001193125-26-267599 | STERIS plc names ResMed Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |